REDCARE PHARMACY NV (RDC.DE) Stock Fundamental Analysis

Europe • Frankfurt Stock Exchange • FRA:RDC • NL0012044747

59.95 EUR
-0.4 (-0.66%)
Last: Feb 3, 2026, 05:29 PM
Fundamental Rating

3

Taking everything into account, RDC scores 3 out of 10 in our fundamental rating. RDC was compared to 25 industry peers in the Consumer Staples Distribution & Retail industry. While RDC seems to be doing ok healthwise, there are quite some concerns on its profitability. RDC is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year RDC has reported negative net income.
  • In the past year RDC had a positive cash flow from operations.
  • RDC had negative earnings in each of the past 5 years.
  • Of the past 5 years RDC 4 years had a positive operating cash flow.
RDC.DE Yearly Net Income VS EBIT VS OCF VS FCFRDC.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

  • RDC has a Return On Assets of -2.88%. This is amonst the worse of the industry: RDC underperforms 80.00% of its industry peers.
  • RDC's Return On Equity of -7.01% is on the low side compared to the rest of the industry. RDC is outperformed by 80.00% of its industry peers.
Industry RankSector Rank
ROA -2.88%
ROE -7.01%
ROIC N/A
ROA(3y)-5.45%
ROA(5y)-5.79%
ROE(3y)-11.19%
ROE(5y)-11.08%
ROIC(3y)N/A
ROIC(5y)N/A
RDC.DE Yearly ROA, ROE, ROICRDC.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5 -10 -15 -20

1.3 Margins

  • Looking at the Gross Margin, with a value of 22.88%, RDC is doing worse than 60.00% of the companies in the same industry.
  • In the last couple of years the Gross Margin of RDC has grown nicely.
  • RDC does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 22.88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.88%
GM growth 5Y3.23%
RDC.DE Yearly Profit, Operating, Gross MarginsRDC.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20

More info and screens

5

2. Health

2.1 Basic Checks

  • RDC does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for RDC has been reduced compared to 1 year ago.
  • Compared to 5 years ago, RDC has more shares outstanding
  • Compared to 1 year ago, RDC has a worse debt to assets ratio.
RDC.DE Yearly Shares OutstandingRDC.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
RDC.DE Yearly Total Debt VS Total AssetsRDC.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

  • RDC has an Altman-Z score of 3.23. This indicates that RDC is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of RDC (3.23) is better than 68.00% of its industry peers.
  • A Debt/Equity ratio of 0.62 indicates that RDC is somewhat dependend on debt financing.
  • RDC has a Debt to Equity ratio of 0.62. This is in the better half of the industry: RDC outperforms 76.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF N/A
Altman-Z 3.23
ROIC/WACCN/A
WACC6.63%
RDC.DE Yearly LT Debt VS Equity VS FCFRDC.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

  • RDC has a Current Ratio of 1.68. This is a normal value and indicates that RDC is financially healthy and should not expect problems in meeting its short term obligations.
  • RDC has a better Current ratio (1.68) than 92.00% of its industry peers.
  • RDC has a Quick Ratio of 1.23. This is a normal value and indicates that RDC is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.23, RDC belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.68
Quick Ratio 1.23
RDC.DE Yearly Current Assets VS Current LiabilitesRDC.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

  • The earnings per share for RDC have decreased strongly by -39.61% in the last year.
  • RDC shows a strong growth in Revenue. In the last year, the Revenue has grown by 26.68%.
  • The Revenue has been growing by 27.59% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-39.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.86%
Revenue 1Y (TTM)26.68%
Revenue growth 3Y30.76%
Revenue growth 5Y27.59%
Sales Q2Q%25.18%

3.2 Future

  • RDC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 52.00% yearly.
  • Based on estimates for the next years, RDC will show a quite strong growth in Revenue. The Revenue will grow by 18.39% on average per year.
EPS Next Y48.65%
EPS Next 2Y45.01%
EPS Next 3Y45.59%
EPS Next 5Y52%
Revenue Next Year25.07%
Revenue Next 2Y22.35%
Revenue Next 3Y20.54%
Revenue Next 5Y18.39%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
RDC.DE Yearly Revenue VS EstimatesRDC.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2B 4B 6B
RDC.DE Yearly EPS VS EstimatesRDC.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 5 10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RDC. In the last year negative earnings were reported.
  • With a Price/Forward Earnings ratio of 302.50, RDC can be considered very expensive at the moment.
  • 88.00% of the companies in the same industry are cheaper than RDC, based on the Price/Forward Earnings ratio.
  • RDC is valuated expensively when we compare the Price/Forward Earnings ratio to 25.64, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 302.5
RDC.DE Price Earnings VS Forward Price EarningsRDC.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 100 200 300

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of RDC indicates a rather expensive valuation: RDC more expensive than 84.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 33.93
RDC.DE Per share dataRDC.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 50 100

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • A more expensive valuation may be justified as RDC's earnings are expected to grow with 45.59% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y45.01%
EPS Next 3Y45.59%

More info and screens

0

5. Dividend

5.1 Amount

  • RDC does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

REDCARE PHARMACY NV

FRA:RDC (2/3/2026, 5:29:46 PM)

59.95

-0.4 (-0.66%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupConsumer Staples Distribution & Retail
GICS IndustryConsumer Staples Distribution & Retail
Earnings (Last)01-07
Earnings (Next)N/A
Inst Owners51.62%
Inst Owner ChangeN/A
Ins Owners7.32%
Ins Owner ChangeN/A
Market Cap1.23B
Revenue(TTM)2.82B
Net Income(TTM)-35.19M
Analysts80
Price Target138.07 (130.31%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)150.51%
Min EPS beat(2)-12.8%
Max EPS beat(2)313.82%
EPS beat(4)2
Avg EPS beat(4)71.29%
Min EPS beat(4)-42.68%
Max EPS beat(4)313.82%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-1.34%
Min Revenue beat(2)-1.55%
Max Revenue beat(2)-1.13%
Revenue beat(4)0
Avg Revenue beat(4)-1.42%
Min Revenue beat(4)-2.24%
Max Revenue beat(4)-0.77%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.22%
PT rev (3m)-12.1%
EPS NQ rev (1m)0%
EPS NQ rev (3m)39.28%
EPS NY rev (1m)-7.56%
EPS NY rev (3m)-1.52%
Revenue NQ rev (1m)-1.75%
Revenue NQ rev (3m)-2.87%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 302.5
P/S 0.44
P/FCF N/A
P/OCF 37.6
P/B 2.46
P/tB 12.39
EV/EBITDA 33.93
EPS(TTM)-1.75
EYN/A
EPS(NY)0.2
Fwd EY0.33%
FCF(TTM)-2.99
FCFYN/A
OCF(TTM)1.59
OCFY2.66%
SpS137.07
BVpS24.41
TBVpS4.84
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -2.88%
ROE -7.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 22.88%
FCFM N/A
ROA(3y)-5.45%
ROA(5y)-5.79%
ROE(3y)-11.19%
ROE(5y)-11.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.88%
GM growth 5Y3.23%
F-Score3
Asset Turnover2.31
Health
Industry RankSector Rank
Debt/Equity 0.62
Debt/FCF N/A
Debt/EBITDA 8.5
Cap/Depr 136.74%
Cap/Sales 3.34%
Interest Coverage N/A
Cash Conversion 90.05%
Profit Quality N/A
Current Ratio 1.68
Quick Ratio 1.23
Altman-Z 3.23
F-Score3
WACC6.63%
ROIC/WACCN/A
Cap/Depr(3y)87.99%
Cap/Depr(5y)151.24%
Cap/Sales(3y)2.78%
Cap/Sales(5y)3.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-39.61%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-2.86%
EPS Next Y48.65%
EPS Next 2Y45.01%
EPS Next 3Y45.59%
EPS Next 5Y52%
Revenue 1Y (TTM)26.68%
Revenue growth 3Y30.76%
Revenue growth 5Y27.59%
Sales Q2Q%25.18%
Revenue Next Year25.07%
Revenue Next 2Y22.35%
Revenue Next 3Y20.54%
Revenue Next 5Y18.39%
EBIT growth 1Y-72.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year303.02%
EBIT Next 3Y93.89%
EBIT Next 5Y68.49%
FCF growth 1Y-2656.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-18.32%
OCF growth 3Y23.87%
OCF growth 5YN/A

REDCARE PHARMACY NV / RDC.DE FAQ

What is the ChartMill fundamental rating of REDCARE PHARMACY NV (RDC.DE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to RDC.DE.


Can you provide the valuation status for REDCARE PHARMACY NV?

ChartMill assigns a valuation rating of 1 / 10 to REDCARE PHARMACY NV (RDC.DE). This can be considered as Overvalued.


Can you provide the profitability details for REDCARE PHARMACY NV?

REDCARE PHARMACY NV (RDC.DE) has a profitability rating of 1 / 10.


What is the expected EPS growth for REDCARE PHARMACY NV (RDC.DE) stock?

The Earnings per Share (EPS) of REDCARE PHARMACY NV (RDC.DE) is expected to grow by 48.65% in the next year.